New hope for tough colon cancer: combo therapy targets BRAF mutation
Disease control
Not yet recruiting
This phase 2 trial tests a new immunotherapy drug (aipalolitovorelizumab) combined with standard chemotherapy and bevacizumab in 30 people with metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR type. The goal is to see if the combination shrinks tumors a…
Phase: PHASE2 • Sponsor: Yanqiao Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC